NeuroSense Therapeutics L... (NRSN)
1.02
-0.01 (-0.97%)
At close: Jan 15, 2025, 10:57 AM
Company Description
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases.
Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis.
The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease.
NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
NeuroSense Therapeutics Ltd.
| Country | IL |
| IPO Date | Dec 9, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | Alon Ben-Noon |
Contact Details
Address: Building B Herzliya, IL | |
| Website | https://www.neurosense-tx.com |
Stock Details
| Ticker Symbol | NRSN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001875091 |
| CUSIP Number | M74240108 |
| ISIN Number | IL0011809592 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Alon Ben-Noon | Co-Founder, Chief Executive Officer & Director |
| Dr. Niva Russek-Blum Ph.D. | Chief Technology Officer |
| Or Eisenberg | Chief Financial Officer |
| Dr. Ferenc Tracik M.D. | Chief Medical Officer |
| Eidan Loushi | C.R.A. |
| Hagit Binder | Chief Operation Officer |
| Keren Pushett | Head of HR |
| Yael Barak | Vice President of Quality & Compliance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 06, 2025 | 6-K | Filing |
| Dec 26, 2024 | F-3 | Filing |
| Dec 23, 2024 | 6-K | Filing |
| Dec 18, 2024 | 6-K | Filing |
| Dec 17, 2024 | 6-K | Filing |
| Dec 12, 2024 | 424B3 | Filing |
| Dec 12, 2024 | D | Filing |
| Dec 11, 2024 | 6-K | Filing |
| Dec 09, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Dec 06, 2024 | F-3 | Filing |